Tecan Group Ltd. provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories.
No risks detected for TECN from our risk checks.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Tecan Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TECN has not had significant price volatility in the past 3 months.
7 Day Return
CH Life Sciences
1 Year Return
CH Life Sciences
Return vs Industry: TECN underperformed the Swiss Life Sciences industry which returned 45% over the past year.
Return vs Market: TECN exceeded the Swiss Market which returned 16.2% over the past year.
Price Volatility Vs. Market
How volatile is Tecan Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Kind Of Investor Owns Most Of Tecan Group Ltd. (VTX:TECN)?
1 month ago | Simply Wall StInvestors Who Bought Tecan Group (VTX:TECN) Shares Five Years Ago Are Now Up 207%
1 month ago | Simply Wall StDo You Like Tecan Group Ltd. (VTX:TECN) At This P/E Ratio?
Is Tecan Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TECN (CHF291.8) is trading above our estimate of fair value (CHF266.18)
Significantly Below Fair Value: TECN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TECN is good value based on its PE Ratio (51.5x) compared to the Life Sciences industry average (55.1x).
PE vs Market: TECN is poor value based on its PE Ratio (51.5x) compared to the Swiss market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: TECN is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: TECN is overvalued based on its PB Ratio (5.6x) compared to the XE Life Sciences industry average (4.5x).
How is Tecan Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECN's forecast earnings growth (15.7% per year) is above the savings rate (-0.6%).
Earnings vs Market: TECN's earnings (15.7% per year) are forecast to grow faster than the Swiss market (10.5% per year).
High Growth Earnings: TECN's earnings are forecast to grow, but not significantly.
Revenue vs Market: TECN's revenue (7.7% per year) is forecast to grow faster than the Swiss market (3.3% per year).
High Growth Revenue: TECN's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECN's Return on Equity is forecast to be low in 3 years time (12.4%).
How has Tecan Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TECN has high quality earnings.
Growing Profit Margin: TECN's current net profit margins (10.8%) are lower than last year (12.1%).
Past Earnings Growth Analysis
Earnings Trend: TECN's earnings have grown by 10% per year over the past 5 years.
Accelerating Growth: TECN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TECN had negative earnings growth (-3.2%) over the past year, making it difficult to compare to the Life Sciences industry average (11.5%).
Return on Equity
High ROE: TECN's Return on Equity (10.9%) is considered low.
Return on Assets
Return on Capital Employed
How is Tecan Group's financial position?
Financial Position Analysis
Short Term Liabilities: TECN's short term assets (CHF572.9M) exceed its short term liabilities (CHF160.7M).
Long Term Liabilities: TECN's short term assets (CHF572.9M) exceed its long term liabilities (CHF126.7M).
Debt to Equity History and Analysis
Debt Level: TECN's debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: TECN's debt to equity ratio has reduced from 2.1% to 0.8% over the past 5 years.
Debt Coverage: TECN's debt is well covered by operating cash flow (1752.2%).
Interest Coverage: TECN's interest payments on its debt are well covered by EBIT (103.1x coverage).
Inventory Level: TECN has a high level of physical assets or inventory.
Debt Coverage by Assets: TECN's debt is covered by short term assets (assets are 111.2x debt).
What is Tecan Group's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: TECN's dividend (0.72%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.74%).
High Dividend: TECN's dividend (0.72%) is low compared to the top 25% of dividend payers in the Swiss market (3.38%).
Stability and Growth of Payments
Stable Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TECN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TECN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Achim von Leoprechting (51yo)
Dr. Achim Von Leoprechting, Ph.D., has been Chief Executive Officer of Tecan Group Ltd., since April 1, 2019. He has been Head of the Partnering Business division at Tecan Group Ltd. since October 1, 2013 ...
|Group CFO & Member of Management Board||17.2yrs||CHF1.20m||0.094% CHF3.2m|
|Head of the Partnering Business Division||0.8yrs||no data||0.045% CHF1.5m|
|Executive VP||8.1yrs||no data||0.038% CHF1.3m|
|Executive VP||9.1yrs||no data||0.038% CHF1.3m|
|Executive VP||6.7yrs||no data||0.043% CHF1.4m|
|Executive VP||5.6yrs||no data||0.044% CHF1.5m|
|Head of Corporate Development||2.2yrs||no data||0.011% CHF389.3k|
|CTO, Executive VP||0.5yrs||no data||no data|
|Vice President of Communications & Investor Relations||5.1yrs||no data||no data|
|President of Sales International||0yrs||no data||no data|
Experienced Management: TECN's management team is seasoned and experienced (5.6 years average tenure).
|Independent Director||8.8yrs||CHF141.00k||0.021% CHF716.0k|
|Vice Chairman||12.8yrs||CHF171.00k||0.14% CHF4.7m|
|Independent Director||7.8yrs||CHF139.00k||no data|
|Independent Director||6.8yrs||CHF150.00k||0.022% CHF745.0k|
Experienced Board: TECN's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tecan Group Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Tecan Group Ltd.
- Ticker: TECN
- Exchange: SWX
- Founded: 1980
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF3.403b
- Shares outstanding: 11.87m
- Website: https://www.tecan.com
Number of Employees
- Tecan Group Ltd.
- Seestrasse 103
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TEN||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Jun 1999|
|TECN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Jun 1999|
|TCHB.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Jun 1999|
|0QLN||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Jun 1999|
Tecan Group Ltd. provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company develops, produces, markets, and supports automated workflow solutions, including laboratory instruments, software packages, application knowhow, services, consumables, and spare parts for molecular diagnostics, tissue diagnostics, immunodiagnostics, and mass spectrometry diagnostics; and develops and manufactures original equipment manufacturer instruments and components. Its products include liquid handling and automation products, microplate readers and washers, software, consumables, immunoassays and antibodies, and microarray products. The company operates in Switzerland, the Americas, Other European countries, Asia, and internationally. Tecan Group Ltd. was founded in 1980 and is headquartered in Männedorf, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 21:05|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.